The gut microbiome is a complex, interconnected ecosystem of species. And, like any ecosystem, some organisms are predators and some are prey. A new study led by investigators at Brigham and Women's Hospital and the Wyss Institute investigates the impact of bacteriophage, viruses that infect and kill bacteria. They find that phage can have a profound impact on the dynamics of the gut microbiome, not only affecting certain species directly but also having a cascading effect on others. Phage may also be impacting their human host by modulating metabolites, including chemical substances found in the brain. The team, which includes first author Bryan Hsu, PhD, and co-corresponding senior author Pamela Silver, PhD, at the Wyss Institute, and Lynn Bry, MD, PhD, at the Brigham and director of the Massachusetts Host-Microbiome Center, has published its results in Cell Host & Microbe.
"One of the major interests in my lab is understanding the changes in the dynamics of the gut microbiome. Bacteriophage are a huge component of the microbiome but haven't been studied much yet," said co-corresponding senior author Georg Gerber, MD, PhD, MPH, co-director of the Massachusetts Host-Microbiome Center and chief of the Division of Computational Pathology in the Department of Pathology at the Brigham. "Some people are exploring phage therapy, using phage to kill off microbes, but phage are also found naturally in the gut, co-existing with the rest of the ecosystem. We wanted to find out what they are doing in there."
To address this question, the team colonized the guts of mice with a defined set of human bacterial species and then added phages, tracking the growth of each microbe. Using high-throughput sequencing and computational analyses, the team found that the phage caused attritions of the species they preyed upon as expected, but with a rippling effect on the rest of the ecosystem including blooms of non-targeted species.
In addition to looking at the effects on microbes, the team also looked for effects on the metabolome -- chemical substances that can come from both the host and the bacteria present. They found that when they modulated the microbiome with phage, they could see targeted changes in the metabolome, including changes in neurotransmitter levels and bile acids.
"This finding fascinates me for followup and raises significant questions: Could we use phage to modulate these activities? Could this be an intervention for conditions, such as depression, where you'd want to change neurotransmitter levels?" said Gerber. "Even if they aren't used as a direct therapeutic, our study suggests that phage may be a good tool for understanding the potential effects of other therapeutics that alter the microbiome."
Gerber and colleagues are especially interested in looking at the intersection of phage and malnutrition in the developing world, given the profound effects on the metabolome and microbiome that malnutrition can have.
"We hope that our work will provide a framework to guide future investigations to elucidate the interplay between phage, the microbiota, and host health and disease," said Gerber.
Funding for this work was provided by the Bill & Melinda Gates Foundation through the
Grand Challenges Explorations Initiative (OPP1150555), the Defense Advanced Research Program Agency (DARPA BRICS HR0011-15-C-0094), the National Institutes of Health (T32 HL007627) and a Rosenbloom postdoctoral fellowship. Gerber is a shareholder and member of the Strategic Advisory Board of Kaleido Biosciences, and shareholder and member of the Scientific Advisory Board of Consortia Therapeutics. Another co-author is a shareholder and Chair of the Scientific Advisory Board for Consortia Therapeutics, and shareholder and member of the Strategic Advisory Board for Inspirata, Inc.
Paper cited: Hsu, B et al. "Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model" Cell Host & Microbe DOI: 10.1016/j.chom.2019.05.001